Insights into binding modes of 5-HT2c receptor antagonists with ligand-based and receptor-based methods

被引:0
|
作者
Chunhua Lu
Fangfang Jin
Cui Li
Weihua Li
Guixia Liu
Yun Tang
机构
[1] East China University of Science and Technology,School of Pharmacy
来源
Journal of Molecular Modeling | 2011年 / 17卷
关键词
Docking; Homology modeling; 5-HT2c receptor; 5-HT2c receptor antagonist; Pharmacophore;
D O I
暂无
中图分类号
学科分类号
摘要
5-hydroxytryptamine-2c (5-HT2c) receptor antagonists have clinical utility in the management of nervous system. In this work, ligand-based and receptor-based methods were used to investigate the binding mode of h5-HT2c receptor antagonists. First, the pharmacophore modeling of the h5-HT2c receptor antagonists was carried out by CATALYST. Then, the h5-HT2c antagonists were docked to the h5-HT2c receptor model. Subsequently, the comprehensive analysis of the pharmacophore and docking results revealed the structure-activity relationship of 5-HT2c receptor antagonists and the key residues involved in the interactions. For example, three hydrophobic points in the ligands corresponded to the region surrounded by Val135, Val208, Phe214, Ala222, Phe327, Phe328 and Val354 of the h5-HT2c receptor. The carbonyl group of compound 1 formed a hydrogen bond with Asn331. The nitrogen atom in the piperidine of compound 1 corresponding to the positive ionizable position of the best pharmacophore formed the electrostatic interactions with the carbonyl of Asp134, Asn331 and Val354, and with the hydroxyl group of Ser334. In addition, a predictive CoMFA model was developed based on the 24 compounds that were used as the training set in the pharmacophore modeling. Our results were not only useful to explore the detailed mechanism of the interactions between the h5-HT2c receptor and antagonists, but also provided suggestions in the discovery of novel 5-HT2c receptor antagonists.
引用
收藏
页码:2513 / 2523
页数:10
相关论文
共 50 条
  • [31] Indolines as 5-HT2C receptor ligands.
    Pratt, RM
    Adams, DR
    Bebbington, D
    Bentley, JM
    Benwell, K
    Bickerdike, MJ
    Cliffe, IA
    Davidson, JEP
    Dawson, CE
    Duncton, MAJ
    Gaur, S
    George, AR
    Giles, PR
    Hamlyn, RJ
    Kennett, GA
    Knight, T
    Malcolm, C
    Mansell, HL
    Misra, A
    Monck, NJT
    Roffey, JR
    Vickers, S
    Dourish, CT
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2002, 224 : U67 - U67
  • [32] Activating mutations of the serotonin 5-HT2C receptor
    HerrickDavis, K
    Egan, C
    Teitler, M
    JOURNAL OF NEUROCHEMISTRY, 1997, 69 (03) : 1138 - 1144
  • [33] Roles of the 5-HT2C receptor on zebrafish sociality
    Moura, Layana Aquino de
    Pyterson, Maryana Pereira
    Pimentel, Ana Flavia Nogueira
    Araujo, Fernanda
    Souza, Loanne Valeria Xavier Bruce de
    Mendes, Caio Henrique Moura
    Costa, Bruna Patricia Dutra
    Siqueira-Silva, Diogenes Henrique de
    Maximino, Monica Lima-
    Maximino, Caio
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2023, 125
  • [34] 5-HT2C receptor modulation and the treatment of obesity
    Bickerdike, MJ
    Vickers, SP
    Dourish, CT
    DIABETES OBESITY & METABOLISM, 1999, 1 (04): : 207 - 214
  • [35] Therapeutic Potential of 5-HT2C Receptor Ligands
    Jensen, Nanna H.
    Cremers, Thomas I.
    Sotty, Florence
    THESCIENTIFICWORLDJOURNAL, 2010, 10 : 1870 - 1885
  • [36] FUNCTIONAL SELECTIVITY OF 5-HT2C RECEPTOR AGONISTS
    Pausch, Mark
    SCHIZOPHRENIA BULLETIN, 2009, 35 : 339 - 339
  • [37] 5-HT2C receptor modulators: a patent survey
    Lee, Junwon
    Jung, Myung Eun
    Lee, Jinhwa
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2010, 20 (11) : 1429 - 1455
  • [38] A 5-HT2C receptor agonist for the treatment of obesity?
    Van Baak, M
    Lentjes, M
    Mujakovic, S
    Slaap, B
    Saris, W
    OBESITY RESEARCH, 2003, 11 : A110 - A111
  • [39] Allelic variation of the 5-HT2C receptor in psychosis
    Sodhi, MS
    Kirov, G
    Aitchison, KJ
    Arranz, MJ
    Collier, DA
    Kerwin, RW
    SCHIZOPHRENIA RESEARCH, 1997, 24 (1-2) : 90 - 91
  • [40] Indoline derivatives as 5-HT2C receptor agonists
    Bentley, JM
    Adams, DR
    Bebbington, D
    Benwell, KR
    Bickerdike, MJ
    Davidson, JEP
    Dawson, CE
    Dourish, CT
    Duncton, MAJ
    Gaur, S
    George, AR
    Giles, PR
    Hamlyn, RJ
    Kennett, GA
    Knight, AR
    Malcolm, CS
    Mansell, HL
    Misra, A
    Monck, NJT
    Pratt, RM
    Quirk, K
    Roffey, JRA
    Vickers, SP
    Cliffe, IA
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (09) : 2367 - 2370